Myriad Genetics (MYGN) PT Lifted to $42 at Mizuho Securities Post Q1; Remains Sidelined

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. SMCI
8. RTX
9. S
10. COF

Go back to Myriad Genetics (MYGN) PT Lifted to $42 at Mizuho Securities Post Q1; Remains Sidelined

Myriad Genetics Reports Fiscal First-Quarter 2016 Financial Results

November 3, 2015 4:06 PM EST

Total Revenues of $183.5 Million Adjusted Diluted EPS of $0.41 and Diluted EPS of $0.37 Myriad Completes Conversion of Targeted Physicians to myRisk Hereditary Cancer Company Maintains Fiscal Year 2016 Financial Guidance and provides Fiscal Second-Quarter 2016 Financial Guidance

SALT LAKE CITY, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced financial results for its fiscal first-quarter 2016, provided an update on recent business highlights, maintained its fiscal year 2016 financial guidance and provided fiscal second-quarter 2016 financial guidance.

"We were very... More